A phase II trial of chemoradiotherapy using weekly docetaxel for high-risk postoperative oral squamous cell carcinoma patients.

Rongrong Li,Wen Jiang,Shengjin Dou,Laiping Zhong,Jian Sun,Chenping Zhang,Guopei Zhu

International Journal of Radiation Oncology*Biology*Physics（2020）

引用 3|浏览14

暂无评分

摘要

The addition of low-dose weekly docetaxel with concurrent radiotherapy is a tolerable regimen with favorable DFS and OS in patients with high-risk, resected OSCC.

查看译文

关键词

Docetaxel,High-risk patients,Oral squamous cell carcinoma,Postoperative chemoradiotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要